Pfizer’s Celebrex Could Face Generic At-Risk Launches In May
This article was originally published in The Pink Sheet Daily
Pfizer had hoped to gain an extra 18 months of patent protection with a reissue patent granted last year but a district court ruled the method of use patent is invalid.
You may also be interested in...
Pfizer sues five generic firms alleging their celecoxib ANDAs infringe a reissued method-of-use patent, which protects the blockbuster COX-2 inhibitor until December 2015, 18 months longer than had been expected.
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.